Skip to content
10-Q

Quarterly Report

AYTU BIOPHARMA, INC AYTU

0001437749-25-034825

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Nov 1, 2025 10.19M sh
Shares Diluted Q1 2026 · Sep 30, 2025 19.48M sh
Shares Diluted Q1 2026 · Sep 30, 2024 9.1M sh
Capex Q1 2026 · Sep 30, 2025 $0
Capex Q1 2026 · Sep 30, 2024 $136K
Operating Cash Flow Q1 2026 · Sep 30, 2025 −$618K
Operating Cash Flow Q1 2026 · Sep 30, 2024 −$1.19M
Long Term Debt Q1 2026 · Sep 30, 2025 $10.45M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $32.63M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $30.95M
Stockholders Equity Q1 2026 · Sep 30, 2025 $23.17M
Stockholders Equity Q1 2026 · Jun 30, 2025 $18.97M
Stockholders Equity Q1 2026 · Sep 30, 2024 $29.83M
Stockholders Equity Q1 2026 · Jun 30, 2024 $27.72M
Current Liabilities Q1 2026 · Sep 30, 2025 $65.99M
Current Liabilities Q1 2026 · Jun 30, 2025 $63.06M
Current Assets Q1 2026 · Sep 30, 2025 $81.11M
Current Assets Q1 2026 · Jun 30, 2025 $79.18M
Total Assets Q1 2026 · Sep 30, 2025 $124.99M
Total Assets Q1 2026 · Jun 30, 2025 $124.18M
Eps Diluted Q1 2026 · Sep 30, 2025 −$0.08
Eps Diluted Q1 2026 · Sep 30, 2024 −$0.15
Eps Basic Q1 2026 · Sep 30, 2025 $0.21
Eps Basic Q1 2026 · Sep 30, 2024 $0.24
Rd Expense Q1 2026 · Sep 30, 2025 $0
Rd Expense Q1 2026 · Sep 30, 2024 $426K
Net Income Q1 2026 · Sep 30, 2025 $1.97M
Net Income Q1 2026 · Sep 30, 2024 $1.47M
Operating Income Q1 2026 · Sep 30, 2025 −$1.5M
Operating Income Q1 2026 · Sep 30, 2024 −$930K
Gross Profit Q1 2026 · Sep 30, 2025 $9.19M
Gross Profit Q1 2026 · Sep 30, 2024 $11.99M
Revenue Q1 2026 · Sep 30, 2025 $13.89M
Revenue Q1 2026 · Sep 30, 2024 $16.57M